Phase II Trial of Avelumab in Combination With Gemcitabine in Advanced Leiomyosarcoma as a Second-line Treatment
Phase of Trial: Phase II
Latest Information Update: 18 Sep 2019
Price : $35 *
At a glance
- Drugs Avelumab (Primary) ; Gemcitabine (Primary)
- Indications Leiomyosarcoma
- Focus Therapeutic Use
- Acronyms EAGLES
- 13 Feb 2019 Planned End Date changed from 31 Dec 2020 to 28 Feb 2022.
- 13 Feb 2019 Planned primary completion date changed from 31 Dec 2020 to 30 Sep 2021.
- 13 Feb 2019 Status changed from not yet recruiting to recruiting.